Literature DB >> 2252841

Racemates versus enantiomers in drug development: dogmatism or pragmatism?

B Testa1, W F Trager.   

Abstract

Mesh：

Year:  1990        PMID： 2252841     DOI： 10.1002/chir.530020302

Source DB:  PubMed          Journal:  Chirality        ISSN： 0899-0042            Impact factor:   2.437


× No keyword cloud information.
  3 in total

1.  Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity'?

Authors:  Giovanni Lentini
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

Review 2.  Chirality in new drug development. Clinical pharmacokinetic considerations.

Authors:  R L Nation
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

3.  Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni.

Authors:  Isabel Meister; Katrin Ingram-Sieber; Noemi Cowan; Matthew Todd; Murray N Robertson; Claudia Meli; Malay Patra; Gilles Gasser; Jennifer Keiser
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.